Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ERAS is expected to report earnings to rise 16.91% to -12 cents per share on May 08
Q1'25
Est.
$-0.13
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.11
Q1'24
Missed
by $0.03
The last earnings report on March 20 showed earnings per share of -10 cents, beating the estimate of -12 cents. With 1.12M shares outstanding, the current market capitalization sits at 341.34M.